Merck and Moderna say mRNA melanoma vaccine hits goals in late-stage trial

Merck and Moderna's promising mRNA vaccine has shown significant success in preventing the return of melanoma in high-risk patients, according to their late-stage trial results. This breakthrough could revolutionize how we treat and manage skin cancer, offering hope to many battling the disease. While the initial results are encouraging, experts emphasize the need for complete data to fully understand the vaccine's efficacy and safety. This development could mark a major step forward in personalized cancer treatments, leveraging the power of mRNA technology.